AI Summary & Key Takeaways
AI InsightSo, we consider that both IMA and adropin are inappropriate markers for the diagnosis of PE.
📌 3 Key Takeaways
Abstract
Purpose: Pulmonary embolism (PE) is a serious clinical condition and difficult to be diagnosed. The aimof the present study was to evaluate plasma adropin and ischemia-modified albumin (IMA) levels in thepatients with PE.Methods: The study consisted of 109 participants, including 50 patients with PE and 59 healthyindividuals. The patients diagnosed with PE through computed tomography pulmonary angiography(CTPA) were included into the study. Plasma adropin and IMA concentrations were measured by anenzyme-linked immunosorbent assay kit.Results: The patients with PE had higher plasma adropin (607.5±205.1 ng/mL) and lower IMA(2128.6±801.8 ng/mL) levels, compared with those in the controls (505.5±231.3 ng/mL and2466.9±1044.9 ng/mL, respectively); however, the difference was not significant. In the study, we founda weak and negative correlation between adropin and IMA levels in the patients with PE (p=0.020, r=-0.348).Conclusions: In our study among the patients with PE, there was no significant difference betweenadropin and IMA levels, although plasma atropin concentrations were high, and IMA concentrations werelow. So, we consider that both IMA and adropin are inappropriate markers for the diagnosis of PE.